Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.

David Shao Peng Tan Jack Junjie Chan Robert Hettle Wrik Ghosh Amrita Viswambaram Cindy Chen Yu

Published in: Journal of gynecologic oncology (2021)

Olaparib has a high potential of being a cost-effective maintenance treatment versus RS for patients with BRCA1/2m advanced OC after response to first-line chemotherapy in Singapore.

Keyphrases

locally advanced
public health
squamous cell carcinoma
breast cancer risk
combination therapy
human health
rectal cancer
climate change
chemotherapy induced